80 related articles for article (PubMed ID: 9731522)
1. The APCI1307K allele and breast cancer risk.
Redston M; Nathanson KL; Yuan ZQ; Neuhausen SL; Satagopan J; Wong N; Yang D; Nafa D; Abrahamson J; Ozcelik H; Antin-Ozerkis D; Andrulis I; Daly M; Pinsky L; Schrag D; Gallinger S; Kaback M; King MC; Woodage T; Brody LC; Godwin A; Warner E; Weber B; Foulkes W; Offit K
Nat Genet; 1998 Sep; 20(1):13-4. PubMed ID: 9731522
[No Abstract] [Full Text] [Related]
2. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews.
Woodage T; King SM; Wacholder S; Hartge P; Struewing JP; McAdams M; Laken SJ; Tucker MA; Brody LC
Nat Genet; 1998 Sep; 20(1):62-5. PubMed ID: 9731533
[TBL] [Abstract][Full Text] [Related]
3. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.
Figer A; Karasik YP; Baruch RG; Chetrit A; Papa MZ; Sade RB; Rizel S; Friedman E
Isr Med Assoc J; 2002 Oct; 4(10):759-62. PubMed ID: 12389335
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.
Jakubowska A; Narod SA; Goldgar DE; Mierzejewski M; Masojć B; Nej K; Huzarska J; Byrski T; Górski B; Lubiński J
Cancer Epidemiol Biomarkers Prev; 2003 May; 12(5):457-9. PubMed ID: 12750242
[TBL] [Abstract][Full Text] [Related]
7. Excess risk of colon cancer associated with a polymorphism of the APC gene?
White RL
Cancer Res; 1998 Sep; 58(18):4038-9. PubMed ID: 9751604
[No Abstract] [Full Text] [Related]
8. I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer.
Nathanson KL; Antin-Ozerkis D; Couch FJ; Weber BL
Am J Med Genet; 1999 Jul; 85(2):189-90. PubMed ID: 10406676
[No Abstract] [Full Text] [Related]
9. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
[TBL] [Abstract][Full Text] [Related]
11. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
12. The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer.
Yuan ZQ; Bégin LR; Wong N; Brunet JS; Trifiro M; Gordon PH; Pinsky L; Foulkes WD
Br J Cancer; 1999 Nov; 81(5):850-4. PubMed ID: 10555757
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risks for BRCA1/2 carriers.
Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
[No Abstract] [Full Text] [Related]
14. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
15. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Bell DW; Erban J; Sgroi DC; Haber DA
Cancer Res; 2002 May; 62(10):2741-3. PubMed ID: 12019146
[TBL] [Abstract][Full Text] [Related]
16. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
18. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
19. Cancer. A risky business--assessing breast cancer risk.
Levy-Lahad E; Plon SE
Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
[No Abstract] [Full Text] [Related]
20. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers.
Gershoni-Baruch R; Patael Y; Dagan ; Figer A; Kasinetz L; Kadouri E; Bruchim Bar Sade R; Friedman E
Br J Cancer; 2000 Jul; 83(2):153-5. PubMed ID: 10901363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]